Normalcy of diet (mean worst ability to eat, 1 to 4 scale) · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in normalcy of diet (mean worst ability to eat, 1 to 4 scale) compared with placebo; GRADE not reported.
1 finding from 1 review
Oral mucositis (any severity) · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in oral mucositis (any severity) compared with placebo; GRADE not reported.
4 findings from 1 review
RR 0.96 [0.88, 1.05]
4 studies · 655 participants
GRADE not reported
Two studies of KGF versus placebo in children were unclear in reporting; no usable data could be presented
2 studies
GRADE not reported
RR 0.95 [0.90, 1.00]
2 studies · 374 participants
GRADE not reported
Show 1 more finding
Number of days in hospital · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in number of days in hospital compared with placebo; GRADE not reported.
1 finding from 1 review
Number of days unable to take medicine orally · Adults with cancer receiving treatment
The review found no eligible studies for this question.
1 finding from 1 review
Oral mucositis (moderate to severe) · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… may leads to lower oral mucositis (moderate to severe) compared with placebo (low certainty).
3 findings from 1 review
RR 0.89 [0.80, 0.99]
6 studies · 852 participants
Low
RR 0.91 [0.83, 1.00]
3 studies · 471 participants
Moderate
RR 0.56 [0.45, 0.70]
4 studies · 344 participants
Moderate
Oral pain · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in oral pain (mean worst pain, 0 to 10 scale) compared with placebo; GRADE not reported.
2 findings from 1 review
Normalcy of diet (supplemental nutrition: TPN, PEG, nasogastric tube or IV hydration) · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in normalcy of diet (supplemental nutrition: TPN, PEG, nasogastric tube… compared with placebo; GRADE not reported.
1 finding from 1 review
Interruptions to cancer treatment (chemotherapy delays/discontinuations) · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in interruptions to cancer treatment (chemotherapy… compared with placebo; GRADE not reported.
1 finding from 1 review
Interruptions to cancer treatment (unscheduled radiotherapy breaks of 5 or more days) · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in interruptions to cancer treatment (unscheduled radiotherapy breaks… compared with placebo; GRADE not reported.
1 finding from 1 review
Oral mucositis (severe) · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… may leads to lower oral mucositis (severe) compared with placebo (low certainty).
3 findings from 1 review
RR 0.30 [0.14, 0.65]
3 studies · 263 participants
Low
RR 0.85 [0.65, 1.11]
6 studies · 852 participants
Low
RR 0.79 [0.69, 0.90]
3 studies · 471 participants
High
Normalcy of diet (total parenteral nutrition) · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in normalcy of diet (total parenteral nutrition) compared with placebo; GRADE not reported.
1 finding from 1 review
Number of days of treatment with opioid analgesics · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in number of days of treatment with opioid analgesics compared with placebo; GRADE not reported.
1 finding from 1 review